Literature DB >> 15922891

Prognostic value of E-cadherin expression in thyroid follicular carcinoma.

E Brecelj1, S Frković Grazio, M Auersperg, M Bracko.   

Abstract

AIMS: To evaluate the expression of E-cadherin, its association with various clinicopathological features and its possible relation with distant metastasis-free survival (DMFS) in follicular carcinoma of the thyroid.
METHODS: E-cadherin expression was assessed immunohistochemically in sections from paraffin embedded tissues in a group of 54 patients with follicular carcinoma and its variants who were followed for a median of 7.25 years.
RESULTS: Reduced E-cadherin expression, defined as <90% of cells showing membrane positivity, was found in 15 tumours and was significantly associated with widely invasive growth, insular morphology and lesser degree of differentiation, but was not related to patient sex and age or tumour size. In univariate analysis, DMFS was significantly worse in male patients (P<0.03), widely invasive tumours (P=0.0002), moderately/poorly differentiated tumours (P<0.05) and tumours showing reduced E-cadherin expression (P=0.0001). In multivariate analysis, the degree of invasiveness and E-cadherin expression were the only independent prognostic factors. Among widely invasive cases, those with reduced E-cadherin expression had significantly worse DMFS than those with preserved expression.
CONCLUSIONS: Our findings suggest that E-cadherin expression could be used as a prognostic marker in widely invasive follicular carcinomas of the thyroid. Larger studies are needed to assess its prognostic value in the group of minimally invasive carcinomas.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15922891     DOI: 10.1016/j.ejso.2005.02.003

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  8 in total

1.  SKI-606, an Src inhibitor, reduces tumor growth, invasion, and distant metastasis in a mouse model of thyroid cancer.

Authors:  Won Gu Kim; Celine J Guigon; Laura Fozzatti; Jeong Won Park; Changxue Lu; Mark C Willingham; Sheue-yann Cheng
Journal:  Clin Cancer Res       Date:  2012-01-23       Impact factor: 12.531

2.  Dynamic changes in E-cadherin gene promoter methylation during metastatic progression in papillary thyroid cancer.

Authors:  Kirk Jensen; Aneeta Patel; Victoria Hoperia; Alexander Larin; Andrew Bauer; Vasyl Vasko
Journal:  Exp Ther Med       Date:  2010-05-01       Impact factor: 2.447

3.  Association between E-cadherin (CDH1) polymorphisms and papillary thyroid carcinoma risk in Han Chinese population.

Authors:  Ying-Xue Wang; Lei Zhao; Xiu-Yun Wang; Chang-Mei Liu; Su-Guo Yu
Journal:  Endocrine       Date:  2011-12-23       Impact factor: 3.633

Review 4.  Prognostic biomarkers in thyroid cancer.

Authors:  Paula Soares; Ricardo Celestino; Miguel Melo; Elsa Fonseca; Manuel Sobrinho-Simões
Journal:  Virchows Arch       Date:  2014-02-01       Impact factor: 4.064

5.  Proinflammatory mediators upregulate snail in head and neck squamous cell carcinoma.

Authors:  Maie A St John; Mariam Dohadwala; Jie Luo; Guanyu Wang; Gina Lee; Hubert Shih; Eileen Heinrich; Kostantyn Krysan; Tonya Walser; Saswati Hazra; Li Zhu; Chi Lai; Elliot Abemayor; Michael Fishbein; David A Elashoff; Sherven Sharma; Steven M Dubinett
Journal:  Clin Cancer Res       Date:  2009-09-29       Impact factor: 12.531

6.  Clinical importance and therapeutic implication of E-cadherin gene methylation in human ovarian cancer.

Authors:  Xiao Wu; Yi-xuan Zhuang; Chao-qun Hong; Jiong-yu Chen; Yan-jie You; Fan Zhang; Ping Huang; Ming-yao Wu
Journal:  Med Oncol       Date:  2014-06-29       Impact factor: 3.064

7.  Metastatic Follicular Thyroid Carcinoma Secreting Thyroid Hormone and Radioiodine Avid without Stimulation: A Case Report and Literature Review.

Authors:  Syed A Abid; Brendan C Stack; Donald L Bodenner
Journal:  Case Rep Endocrinol       Date:  2014-10-07

8.  Diagnostic impact of promoter methylation and E-cadherin gene and protein expression levels in laryngeal carcinoma.

Authors:  Katarzyna Starska; Ewa Forma; Iwona Lewy-Trenda; Paweł Papież; Jan Woś; Magdalena Bryś
Journal:  Contemp Oncol (Pozn)       Date:  2013-06-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.